Overview
Rectovaginal fistula (RVF) is an abnormal communication between the rectum and vagina, leading to involuntary fecal incontinence and significant morbidity. This condition often results from obstetric trauma, pelvic surgery, radiation therapy, or inflammatory bowel disease. Patients affected are predominantly women, with a notable impact on quality of life due to physical discomfort, psychological distress, and social isolation. Early and effective management is crucial in day-to-day practice to restore continence and improve overall well-being 14.Pathophysiology
The development of a rectovaginal fistula typically arises from a cascade of events involving tissue damage and impaired healing mechanisms. Initial trauma or disease processes, such as obstetric lacerations, surgical complications, or radiation-induced tissue necrosis, disrupt the integrity of the rectal and vaginal walls. This disruption exposes underlying tissues to hostile conditions, promoting inflammation and infection that hinder proper wound healing. The breakdown of local blood supply and compromised cellular repair processes further exacerbate the formation and persistence of the fistula. In cases where patients have undergone multiple surgeries or received radiation therapy, the tissue quality is often compromised, making healing more challenging 1.Epidemiology
Rectovaginal fistulas are relatively rare but have significant clinical implications. Incidence rates vary widely, often ranging from 1 in 1,000 to 1 in 10,000 vaginal deliveries, with higher prevalence noted in regions with limited access to obstetric care. The condition predominantly affects women, particularly those with a history of obstetric injuries, colorectal surgeries, or pelvic radiotherapy. Risk factors include advanced maternal age, prolonged labor, and preexisting conditions like Crohn's disease or ulcerative colitis. Trends suggest an increasing recognition and reporting of RVFs, possibly due to improved diagnostic techniques and heightened awareness among healthcare providers 4.Clinical Presentation
Patients with rectovaginal fistulas typically present with symptoms of fecal incontinence, characterized by involuntary passage of feces through the vagina, often accompanied by a foul-smelling vaginal discharge. Other common symptoms include recurrent urinary tract infections, dyspareunia, and significant psychological distress. Atypical presentations may include intermittent symptoms or those mimicking other pelvic pathologies. Red-flag features include persistent fever, significant weight loss, or signs of systemic infection, which necessitate urgent evaluation and intervention 4.Diagnosis
The diagnosis of rectovaginal fistula involves a comprehensive clinical evaluation followed by specific diagnostic procedures. Initial assessment includes a detailed history and physical examination, focusing on the nature and timing of symptoms. Key diagnostic steps include:Endoscopic Evaluation: High-resolution anoscopy or proctoscopy to visualize the fistula tract.
Fistulography: Contrast studies via rectal or vaginal routes to delineate the fistula path.
Colonic Transit Study: To rule out functional causes of incontinence.
Imaging: MRI or CT scans for detailed anatomical assessment, especially in complex cases.
Culture and Sensitivity: To identify any concurrent infection.Specific Criteria and Tests:
Endoscopic Findings: Visible tract connecting rectum and vagina.
Fistulography: Contrast clearly outlining the fistula tract.
Culture Results: Negative or specific pathogen identification.
Colonic Transit Time: Normal transit time rules out functional causes.
MRI/CT: Confirmation of anatomical defects and extent of damage.Differential Diagnosis:
Vesicovaginal Fistula: Typically associated with urinary leakage, not fecal.
Enterovaginal Fistula: Originates from small bowel, often with different clinical and imaging characteristics.
Pelvic Collection or Abscess: Presents with localized pain and swelling, not continuous fecal leakage 4.Management
First-Line Treatment
Transvaginal Repair Techniques:
Bulbocavernosus Fat Pad Filling: Incise labia majora, fill fistula with fat pad, and retain scar tissue; successful in early cases 3.
Vaginal Mucosa Advancement Flap: Advance vaginal mucosa to cover the fistula site, effective in primary repairs 4.Specifics:
Surgical Technique: Tailored to defect size and patient history.
Avoid Faecal Diversion: Unless indicated by severe contamination or complex anatomy.
Monitoring: Regular follow-up for signs of recurrence or complications.Second-Line Treatment
Surgical Interventions for Complex Cases:
Gracilis Muscle Flap Transposition: Indicated for recurrent or complex fistulas, particularly in patients with multiple prior surgeries or radiation exposure 1.
- Indications: Multiple prior surgeries, radiation history.
- Success Rate: ~72.7% success without recurrence.
- Monitoring: Assess donor site comfort and fistula closure at follow-up visits.Refractory Cases / Specialist Escalation
Multidisciplinary Approach: Collaboration with colorectal surgeons, gynecologists, and radiologists.
Advanced Techniques: Consider bioengineered grafts or newer reconstructive methods.
Consultation: For persistent or complex fistulas, seek expert opinion in specialized centers.Contraindications:
Active infection or sepsis.
Severe systemic illness precluding surgery.Complications
Recurrent Fistula: Common in complex or inadequately repaired cases; requires re-evaluation and revision surgery.
Infection: Risk of postoperative infections, necessitating prompt antibiotic therapy.
Adhesions: Can lead to bowel obstruction; monitored via imaging and clinical symptoms.
Donor Site Issues: In flap procedures, donor site discomfort or complications must be addressed 1.Prognosis & Follow-up
The prognosis for rectovaginal fistula repair varies based on the complexity of the fistula and the patient's overall health. Successful closure rates range from 70% to 90% in well-managed cases, with higher success in primary repairs compared to recurrent fistulas. Prognostic indicators include the absence of infection, adequate tissue quality, and appropriate surgical technique. Follow-up intervals typically include:
Immediate Post-Op: Weekly for the first month.
Subsequent: Monthly for the first six months, then every three months for the first year.
Long-Term: Annually to monitor for recurrence and functional outcomes 4.Special Populations
Pregnancy: Repair should be deferred until postpartum to avoid complications; specialized techniques may be required 3.
Elderly Patients: Consider comorbidities and functional status; multidisciplinary care is essential.
Radiation Therapy History: Higher risk of complications; surgical approaches like gracilis flap transposition may be more beneficial 1.Key Recommendations
Primary Repair with Vaginal Mucosa Advancement Flap: Preferred for uncomplicated cases; success rates are high when performed by experienced surgeons (Evidence: Strong 4).
Avoid Unnecessary Faecal Diversion: Unless indicated by severe contamination or complex anatomy (Evidence: Moderate 4).
Consider Gracilis Muscle Flap for Complex Cases: Particularly useful in patients with multiple prior surgeries or radiation exposure, showing significant success rates (Evidence: Moderate 1).
Multidisciplinary Approach for Refractory Cases: Collaboration with colorectal and gynecological specialists enhances outcomes (Evidence: Expert opinion).
Regular Follow-Up Post-Surgery: Monitor for recurrence and complications with frequent visits in the first year (Evidence: Moderate 4).
Use of Imaging Techniques: Essential for accurate diagnosis and planning complex repairs (Evidence: Moderate 4).
Cultural and Ethnic Considerations: Tailor management strategies considering regional risk factors and access to care (Evidence: Expert opinion).
Psychological Support: Integrate mental health support for patients dealing with the psychological impact of RVF (Evidence: Expert opinion).
Avoid Surgery in Active Infection: Postpone surgical intervention until infection is controlled (Evidence: Strong 14).
Consider Bioengineered Grafts in Refractory Cases: Emerging techniques may offer new solutions for complex fistulas (Evidence: Weak 1).References
1 Park SO, Hong KY, Park KJ, Chang H, Shin JY, Jeong SY. Treatment of rectovaginal fistula with gracilis muscle flap transposition: long-term follow-up. International journal of colorectal disease 2017. link
2 Baric M, Sever AZ, Vuletic LB, Rasic Z, Sever M, Drmic D et al.. Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats. Life sciences 2016. link
3 Le A, Shan L, Wang Z, Dai X, Xiao T, Shen Y. Transvaginal repair of rectovaginal fistula by filling with bulbocavernosus fat pad and retaining scar tissue. Clinical and experimental obstetrics & gynecology 2014. link
4 Casadesus D, Villasana L, Sanchez IM, Diaz H, Chavez M, Diaz A. Treatment of rectovaginal fistula: a 5-year review. The Australian & New Zealand journal of obstetrics & gynaecology 2006. link